B. Metzler Seel. Sohn & Co. Ag Axsome Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.07 Billion
- Q1 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 9,241 shares of AXSM stock, worth $729,392. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,241
Previous 9,241
-0.0%
Holding current value
$729,392
Previous $735,000
0.27%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding AXSM
# of Institutions
290Shares Held
37.1MCall Options Held
401KPut Options Held
464K-
Rtw Investments, LP New York, NY4.49MShares$355 Million5.75% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$295 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.2MShares$252 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$186 Million30.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.3MShares$103 Million3.44% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.38B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...